Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial

Shoji Nagao(Saitama Medical University), Takayuki Enomoto(Niigata University), Karen K. L. Chan(Queen Mary Hospital), Wong Wai Loong(KK Women's and Children's Hospital), Takeshi Hirasawa(Tokai University), Keiichi Fujiwara(Saitama Medical University), Hiroshi Tanabe(Jikei University Kashiwa hospital), Sosuke Adachi(Niigata University), Kazuhiro Takehara(Shikoku Cancer Center), Motoaki Saito(Jikei University School of Medicine), Peter Syks(University of Otago), Tomonori Nagai(Social Insurance Saitama Chuo Hospital), Shoji Kamiura(Osaka International Cancer Institute), David S.P. Tan(National University of Singapore), Aikou Okamoto(Jikei University School of Medicine), Takeshi Yokoi(Takarazuka City Hospital), Eiji Kondo(Mie University), Alexsander Olawaye(Magee-Womens Hospital), Kosei Hasegawa(Saitama Medical University), Akira Fujishita(Nagasaki Ajisai Hospital), Sang‐Young Ryu, Satoshi Yamaguchi(Hyogo Prefectural Cancer Center), Kouji Yamamoto(Yokohama City University), Hiroyuki Fujiwara(Jichi Medical University), Akira Kikuchi(Niigata Cancer Center Hospital), Toyomi Sato(University of Tsukuba), Takashi Matsumoto(Ehime University), Hiroyuki Shigeta(Yokohama Municipal Citizen's Hospital), Yoshihito Yokoyama(Hirosaki University)
NEJM Evidence
April 21, 2023
Cited by 31


Related Papers